MKI67 and breast cancer: According to the American Society of Clinical Oncology (ASCO) guidelines, in postmenopausal patients diagnosed with stage I-II BC, Ki67 expression might be used in combination with other clinical pathological factors to arrive at informed decisions regarding adjuvant endocrine and chemotherapy treatments when multigene assays are not accessible.